The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The COVID-19 treatment was previously authorized for emergency use in hospitalized children and adults, and remains under EUA for hospitalized children.

In other news, FDA yesterday alerted health care providers and the public not to use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) because the agency has not authorized or approved the test and it may produce false results. 

Related News Articles

Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…
Headline
The Centers for Medicare & Medicaid Services Friday released updated guidance on COVID-19 vaccination coverage and reimbursement to help Medicaid, Children…
Headline
The Food and Drug Administration yesterday revised its emergency use authorization for the Johnson & Johnson COVID-19 vaccine to limit its use to…
Headline
COVID-19 vaccinations prevented an estimated 107,000 Medicare hospitalizations between January and May 2021, resulting in $2.6 billion in savings for Medicare…
Headline
Moderna today asked the Food and Drug Administration to authorize for emergency use its COVID-19 vaccine in children aged 6 months through 5 years, citing…
Headline
Starting this week, the Administration will allow all pharmacies in the federal pharmacy program to order free oral antiviral treatments directly from the…